`
`
`
`
`
`
`Paper No. __
`Filed: January 22, 2015
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`ROXANE LABORATORIES, INC. AND
`PAR PHARMACEUTICAL, INC.
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner
`
`_____________________
`
`Case CBM2014-00175
`Patent 7,765,107
`_____________________
`
`
`
`
`
`UPDATED MANDATORY NOTICES BY
`
`ROXANE LABORATORIES, INC. AND PAR PHARMACEUTICAL, INC.
`
`UNDER 37 C.F.R. § 42.8(A)(3); §42.8(B)(2)
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`

`

`
`
`
`
`Case CBM2014-00175
`Patent 7,765,107
`Petitioners’ Updated Mandatory Notices
`
`Pursuant to 37 C.F.R. §§ 42.8(a)(3) and 42.8(b)(2), Petitioners submit updated mandatory
`
`notices regarding related matters. This document in addition to providing further information
`
`about a related proceeding responds to the Patent Owner’s submission dated January 14, 2015
`
`(CBM2014-00175, Paper 11).
`
`
`
`Pursuant to 37 C.F.R. § 42.8(b)(1), Petitioners are the real party in interest as petitioners
`
`for the reasons set forth in the Petition.
`
`
`
`Pursuant to 37 C.F.R. § 42.8(b)(2) the Decision Denying Institution of Covered Business
`
`Method Review (see CBM2014-00149) (“the Decision”) is a related proceeding in that the
`
`patent that is the subject matter of this Petition (United States Patent No. 7,765,107) (“the ‘107
`
`patent”) is from the same patent family as the patents that were the subject of the Decision.
`
`
`
`However, the grounds for denial of institution in the Decision turned on the claim
`
`language of the patents that are the subject of the Decision as not reciting the required financial
`
`step. In contrast, as set forth in the instant Petition (see CBM2014-00175), the claims of the ‘107
`
`patent contain different language concerning insurance payment and cash payments. Thus, the
`
`‘107 patent claims recite or require method steps “used in the practice, administration, or
`
`management of a financial product or service” as defined in Section 18(d)(1) of the AIA.
`
`Therefore, Petitioners respectfully submit that merely because the ‘107 patent has a familial
`
`relation to the ‘730, ‘059, ‘182 and ‘988 patents, the Decision should not affect PTAB’s decision
`
`in this proceeding.
`
`
`
`Therefore, Petitioners respectfully request that the Board institute covered business
`
`method review of the ‘107 patent.
`
`Date: January 22, 2015
`
`Respectfully submitted,
`
`By:
`
`/Alan B. Clement (Reg. No. 34,563)/
`ALAN B. CLEMENT
`REG. NO. 34,563
`
`Attorney for Petitioner
`Locke Lord LLP
`3 World Financial Center
`New York, NY 10281
`212.415.8600 (reception)
`
`
`
`

`

`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`ROXANE LABORATORIES, INC. AND
`PAR PHARMACEUTICAL, INC.
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner
`
`_____________________
`
`Case CBM2014-00175
`Patent 7,765,107
`_____________________
`
`
`
`CERTIFICATE OF SERVICE
`
`
`
`
`
`

`

`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certify that UPDATED
`
`MANDATORY NOTICES BY ROXANE LABORATORIES, INC. AND PAR
`
`PHARMACEUTICAL, INC. UNDER 37 C.F.R. § 42.8(A)(3); §42.8(B)(2) were
`
`served on January 22, 2015 by filing this document through the Patent Review Processing
`
`System, as well as e-mailing a copy to nickcerrito@quinnemanuel.com and
`
`jvbiernacki@jonesday.com.
`
`Date: January 22, 2015
`
`Respectfully submitted,
`
`By: /Alan B. Clement (Reg. 34,563)/
`Alan B. Clement
`Reg. No. 34,563
`
`Attorney for Petitioner
`Locke Lord LLP
`3 World Financial Center
`New York, NY 10281
`212.415.8600 (reception)
`
`
`
`